PTC Therapeutics (NASDAQ:PTCT) versus Precigen (NASDAQ:PGEN) Financial Survey

PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Risk and Volatility

PTC Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Precigen has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares PTC Therapeutics and Precigen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73 billion	3.12	$682.64 million	($0.58)	-111.55
Precigen	$9.68 million	287.64	-$250.64 million	($1.04)	-7.51

PTC Therapeutics has higher revenue and earnings than Precigen. PTC Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PTC Therapeutics and Precigen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Precigen	-183.98%	423.75%	84.39%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for PTC Therapeutics and Precigen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2	2	10	1	2.67
Precigen	1	1	4	0	2.50

PTC Therapeutics presently has a consensus price target of $98.25, indicating a potential upside of 51.85%. Precigen has a consensus price target of $13.67, indicating a potential upside of 74.99%. Given Precigen’s higher possible upside, analysts clearly believe Precigen is more favorable than PTC Therapeutics.

Institutional and Insider Ownership

33.5% of Precigen shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Precigen beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

About Precigen

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.